



JC03 Rec'd PCT PTO 21 OCT 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 05-548)

the Application of:

Van Der Burg et al.

Serial No.: 10/539,455

Filed: June 17, 2005

Title: Method for Determining the Presence of
One or More Ligands in a Sample

) Art Unit: Unknown

) Examiner: Not Assigned

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In regard to the above identified application:


1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement
 - b. Copies of cited Non-U.S. Patent references
 - c. Return Receipt Postcard

2. With respect to additional fees:
 - a. Attached is a check in the amount of \$ -0-

3. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450 on this 19th day of October, 2005.

By :



A. Blair Hughes
Reg. No. 32,901

McDONNELL BOEHNEN,
HULBERT & BERGOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

... A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

st

eet

of | 2

Complete if Known

Application Number	10,539,455
Filing Date	June 17, 2005
First Named Inventor	Van Der Burg
Art Unit	Unknown
Examiner Name	Not Assigned
Attorney Docket Number	05-548

Attorney Docket Number 05-548

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
		WO 89/09223	10-5-89	Liao et al.	
		WO 89/09791	10-19-89	French et al.	
		WO 91/07423	5-30-91	Liao et al.	
		EP 0 365 657	8-4-99	French et al.	

Examiner Signature _____ **Date Considered** _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>		Complete if Known	
		Application Number	10/539,455
		Filing Date	June 17, 2005
		First Named Inventor	Van Der Burg
		Art Unit	Unknown
		Examiner Name	Not Assigned
Sheet	2	of	2
		Attorney Docket Number	
		05-548	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Quaedackers, et al., "4-Hydroxytamoxifen Trans-Represses Nuclear Factor-kB Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER)a, and Not Through ERb, Endocrinology, pp. 1156-1166 (2001)	10/539,455 JUN 17 2005 USPTO 2005-06-17
		Grad, et al. "The androgen Receptor (AR) Amino-Terminus Imposes Androgen-Specific Regulation of AR Gene Expression via an Exonic Enhancer, Endocrinology, pp. 1107-16 (2001)	10/539,455 JUN 17 2005 USPTO 2005-06-17
		Rogatsky et al., "Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones", EMBO Journal, pp. 6071-6083 (2001)	10/539,455 JUN 17 2005 USPTO 2005-06-17
		Beato, "Gene Regulation by Steroid Hormones", Cell, pp. 335-355 (1989)	10/539,455 JUN 17 2005 USPTO 2005-06-17
		Legler et al., "Development of a Stably Transfected Estrogen Receptor-Mediated Luciferase Reporter Gene Assay in the Human T47D Breast Cancer Cell Line", Toxicological Science, pp. 55-66 (1999)	10/539,455 JUN 17 2005 USPTO 2005-06-17
		Wilson, et al, "A Novel Cell Line, MDA-kb2, that Stably Expresses an Androgen-and Glucocorticoid-Responsive Reporter for the Detection of Hormone Receptor Agonists and Antagonists", Toxicological Sciences, pp. 69-81 (2002)	10/539,455 JUN 17 2005 USPTO 2005-06-17

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.